If this is a medical emergency, call 10177 (ambulance) or go to your nearest emergency room immediately.
CANSA Patient Support: 0800 22 6622 (toll-free)
This article covers your medical aid rights during a leukaemia-related emergency or coverage crisis. Read it when the immediate medical situation is stable.
What Your Medical Aid Must Cover in an Emergency
Leukaemia is a PMB condition. In a leukaemia-related emergency, your scheme must fund emergency care at any registered hospital — regardless of network status, prior authorisation, or oncology sub-limit position.
Common leukaemia emergencies and PMB obligations:
| Emergency | PMB Status | Notes |
|---|---|---|
| Febrile neutropenia (fever + low white cells post-chemo) | Yes — PMB | Urgent hospitalisation; IV antibiotics; G-CSF support |
| Blast crisis (CML: rapid progression to acute phase) | Yes — PMB | Urgent change in treatment; hospitalisation required |
| Severe anaemia / thrombocytopenia requiring transfusion | Yes — PMB | Blood products funded as PMB |
| Sepsis in an immune-suppressed patient | Yes — emergency PMB | |
| CNS leukaemia (headache, neurological symptoms) | Yes — PMB | LP + intrathecal chemotherapy |
| Tumour lysis syndrome (after starting chemotherapy) | Yes — PMB | ICU monitoring, fluid management |
| Hyperleukocytosis (white cell crisis in new AML/ALL) | Yes — emergency PMB | Leukapheresis or urgent chemotherapy start |
| Intracranial bleeding (thrombocytopenia-related) | Yes — emergency PMB |
Hyperleukocytosis (extremely elevated white cell count at AML/ALL diagnosis) is a specific haematological emergency that can cause organ damage and requires urgent treatment — sometimes before the full diagnostic workup is complete. If your treating team cannot get pre-authorisation in time, proceed with treatment and have your case manager retrospectively process the authorisation as an emergency. The PMB regulations protect you.
Hospital Admission: What to Know
In a genuine emergency: Present at the nearest appropriate facility. Network status is irrelevant in a life-threatening emergency. Notify your scheme's 24-hour emergency line within 24–48 hours.
For acute leukaemia induction (planned): Pre-authorisation for the full induction phase should be in place before hospital admission. If your haematologist has indicated treatment is needed immediately and authorisation has not been issued: call your case manager and explicitly state "This is an oncological emergency — I need same-day pre-authorisation." Follow up every hour if necessary.
For ongoing chemotherapy cycles: Confirm authorisation for each cycle in advance. Your haematologist's rooms can manage this, but verify the authorisation is active before presenting.
If Your Scheme Declines or You Cannot Pay
If your scheme declines a treatment:
- Request written reasons for the decline.
- If it is PMB-classified treatment (standard induction chemotherapy, blood products, emergency admission), appeal in writing with supporting letter from your haematologist.
- Escalate to CMS: 0861 123 267 | www.medicalschemes.co.za. PMB enforcement is legally binding.
If imatinib is declined for CML:
Imatinib is the PMB minimum treatment for CML. A scheme that declines imatinib for CML without clinical justification is in breach of PMB obligations. Submit a formal written appeal immediately and escalate to the CMS if the appeal is declined.
If your sub-limit has run out during AML/ALL treatment:
Standard induction chemotherapy as the PMB minimum treatment cannot be withheld because the sub-limit was reached. The sub-limit governs non-PMB oncology. If your scheme is stopping funding for active first-line chemotherapy, this requires immediate CMS escalation.
Outstanding accounts:
- Request itemised accounts.
- Blood transfusions and ICU management in a haematology admission generate significant billing; check for errors before paying.
- For haematologist and anaesthesiologist shortfalls, contact each practice directly to negotiate a payment plan.
After the Crisis: Next Steps
- Confirm your PMB registration is active and your case manager is assigned.
- Verify sub-limit usage classification — emergency admissions and PMB chemotherapy should not be deducted from the oncology sub-limit.
- Bone marrow transplant planning: If relapse is being discussed, begin BMT pre-authorisation and DSP facility confirmation immediately — do not wait until BMT is urgently needed.
- Benefit year transition (January): For patients on long-term oral TKIs (CML) or maintenance ALL chemotherapy, plan medication continuity across benefit years with your case manager in November–December.
Resources and Helplines
Emergency services: 10177 (ambulance) | 10111 (police) CANSA: 0800 22 6622 (toll-free, weekdays) Leukaemia and Lymphoma SA: llsa.org.za Council for Medical Schemes: 0861 123 267 | www.medicalschemes.co.za Talk to Eldon →